120 related articles for article (PubMed ID: 3704553)
1. Type III aminoterminal propeptide of procollagen in some haematological malignancies.
Arrago JP; Poirier O; Chomienne C; D'Agay MF; Najean Y
Scand J Haematol; 1986 Mar; 36(3):288-94. PubMed ID: 3704553
[TBL] [Abstract][Full Text] [Related]
2. Increased serum procollagen III aminoterminal peptide in myelofibrosis.
Hochweiss S; Fruchtman S; Hahn EG; Gilbert H; Donovan PB; Johnson J; Goldberg JD; Berk PD
Am J Hematol; 1983 Dec; 15(4):343-51. PubMed ID: 6650494
[TBL] [Abstract][Full Text] [Related]
3. [Development of polycythemia to myelofibrosis. Monitoring by the assay of the procollagen III amino-propeptide].
Arrago JP; Poirier O; Najean Y
Presse Med; 1984 Nov; 13(40):2429-32. PubMed ID: 6239221
[TBL] [Abstract][Full Text] [Related]
4. Serum procollagen III peptide in chronic myeloproliferative disorders.
Hasselbalch H; Junker P; Lisse I; Bentsen KD
Scand J Haematol; 1985 Nov; 35(5):550-7. PubMed ID: 4089533
[TBL] [Abstract][Full Text] [Related]
5. Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders.
Hasselbalch H; Junker P; Lisse I; Bentsen KD; Risteli L; Risteli J
Am J Hematol; 1986 Oct; 23(2):101-11. PubMed ID: 3752065
[TBL] [Abstract][Full Text] [Related]
6. The significance of the aminoterminal propeptide of type III procollagen in paroxysmal nocturnal haemoglobinuria and myelofibrosis.
Vellenga E; Mulder NH; van Zanten AK; Nieweg HO; Woldring MG
Eur J Nucl Med; 1983; 8(11):499-501. PubMed ID: 6653612
[TBL] [Abstract][Full Text] [Related]
7. Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy.
Hasselbalch H; Junker P; Hørslev-Petersen K; Lisse I; Bentsen KD
Am J Hematol; 1990 Jan; 33(1):18-26. PubMed ID: 2293759
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of serum pro-collagen III in chronic myeloproliferative disorders.
Najean Y; Legrand M; Poirier O; Senechal A; Arrago JP
Eur J Haematol; 1990 Nov; 45(5):239-43. PubMed ID: 2261948
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum.
Abildgaard N; Bendix-Hansen K; Kristensen JE; Vejlgaard T; Risteli L; Nielsen JL; Heickendorff L
Br J Haematol; 1997 Dec; 99(3):641-8. PubMed ID: 9401078
[TBL] [Abstract][Full Text] [Related]
10. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis.
Zachariae H; Aslam HM; Bjerring P; Søgaard H; Zachariae E; Heickendorff L
J Am Acad Dermatol; 1991 Jul; 25(1 Pt 1):50-3. PubMed ID: 1880254
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP).
Taube T; Franssila K; Risteli L; Risteli J; Elomaa I
Br J Haematol; 1992 Sep; 82(1):32-7. PubMed ID: 1419800
[TBL] [Abstract][Full Text] [Related]
12. [Levels of procollagen type III n-terminal peptide (PIIINP) in serum of patients with myeloproliferative syndrome (mps)].
Podolak-Dawidziak M; Wróbel T; Jeleń M
Pol Arch Med Wewn; 1998 Jan; 99(1):24-9. PubMed ID: 9686500
[TBL] [Abstract][Full Text] [Related]
13. 1 alpha(OH)D3 treatment and procollagen III (PC III) studies in idiopathic myelofibrosis.
Tsatalas C; Curtoglou G; Fotopoulos D; Halkia P; Vyzantiadis AT; Sinakos Z
Haematologica; 1989; 74(6):559-62. PubMed ID: 2628238
[TBL] [Abstract][Full Text] [Related]
14. Collagen metabolism in gynecologic patients: changes in the concentration of the aminoterminal propeptide of type III procollagen in serum.
Puistola U; Risteli L; Risteli J; Kauppila A
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1276-81. PubMed ID: 2220941
[TBL] [Abstract][Full Text] [Related]
15. Aminoterminal propeptide of type III procollagen: a marker of disease activity in schistosomal patients.
Fayol V; Hassanein HI; el-Badrawy N; Ville G; Hartmann DJ
Eur J Clin Chem Clin Biochem; 1991 Nov; 29(11):737-41. PubMed ID: 1782280
[TBL] [Abstract][Full Text] [Related]
16. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
[TBL] [Abstract][Full Text] [Related]
17. [Clinical value of determining the amino terminal fragment of procollagen III in myeloproliferative disorders].
Najean Y; Poirier O; Arrago JP
Nouv Rev Fr Hematol (1978); 1987; 29(2):123-7. PubMed ID: 3615194
[TBL] [Abstract][Full Text] [Related]
18. Splanchnic and renal extraction of circulating type III procollagen aminoterminal propeptide in patients with normal liver function and in patients with alcoholic cirrhosis.
Bentsen KD; Henriksen JH; Bendtsen F; Hørslev-Petersen K; Lorenzen I
Hepatology; 1990 Jun; 11(6):957-63. PubMed ID: 2365293
[TBL] [Abstract][Full Text] [Related]
19. Serum aminoterminal procollagen type III peptide in acute viral hepatitis. A long-term follow-up study.
Bentsen KD; Hørslev-Petersen K; Junker P; Juhl E; Lorenzen I
Liver; 1987 Apr; 7(2):96-105. PubMed ID: 3613881
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of the antigens related to the aminoterminal propeptide of type III procollagen in human serum.
Niemelä O; Risteli L; Sotaniemi EA; Risteli J
Clin Chim Acta; 1982 Sep; 124(1):39-44. PubMed ID: 7127838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]